Market Access What the low impact of Humira biosimilars teaches us about d... Almost everyone seems to agree that drug prices are too high.
Views & Analysis Harmonised health technology assessment in Europe? There's a... Europe is heading towards harmonisation in health technology assessment – but great differences remain in practices and culture
Views & Analysis NICE numbers: trends in recommendations should prompt a revi... Should there be a different review of NICE as part of a successor PPRS?
Views & Analysis Balancing cost:benefit in ‘well-treated’ malignancies The cost: benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them.
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
Views & Analysis Accessing biosimilars: untapped potential in EU and US Though they can reduce the costs of health care, biosimilars still face challenges to access.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends